​

Xencor (XNCR) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Xencor Revenue Highlights

Latest Revenue (Y)

$168.34M

Latest Revenue (Q)

$16.96M

Main Segment (Y)

Milestone

Main Geography (Y)

U

Xencor Revenue by Period

Xencor Revenue by Year

DateRevenueChange
2023-12-31$168.34M2.28%
2022-12-31$164.58M-40.18%
2021-12-31$275.11M124.23%
2020-12-31$122.69M-21.70%
2019-12-31$156.70M285.93%
2018-12-31$40.60M13.70%
2017-12-31$35.71M-59.20%
2016-12-31$87.52M215.25%
2015-12-31$27.76M191.62%
2014-12-31$9.52M-6.41%
2013-12-31$10.17M6.80%
2012-12-31$9.52M39.06%
2011-12-31$6.85M-

Xencor generated $168.34M in revenue during NA 2023, up 2.28% compared to the previous quarter, and up 414.59% compared to the same period a year ago.

Xencor Revenue by Quarter

DateRevenueChange
2024-06-30$16.96M32.45%
2024-03-31$12.80M-71.35%
2023-12-31$44.69M-24.47%
2023-09-30$59.16M29.97%
2023-06-30$45.52M140.07%
2023-03-31$18.96M-12.25%
2022-12-31$21.61M-20.84%
2022-09-30$27.30M-9.53%
2022-06-30$30.18M-64.71%
2022-03-31$85.50M-44.49%
2021-12-31$154.02M682.48%
2021-09-30$19.68M-70.82%
2021-06-30$67.45M98.58%
2021-03-31$33.97M-18.85%
2020-12-31$41.85M18.35%
2020-09-30$35.37M170.20%
2020-06-30$13.09M-59.58%
2020-03-31$32.38M821.08%
2019-12-31$3.52M-83.84%
2019-09-30$21.76M11.68%
2019-06-30$19.48M-82.59%
2019-03-31$111.94M868.00%
2018-12-31$11.56M-60.18%
2018-09-30$29.04M100.00%
2018-06-30-100.00%
2018-03-31--100.00%
2017-12-31$10.94M54.32%
2017-09-30$7.09M-46.85%
2017-06-30$13.34M207.37%
2017-03-31$4.34M-32.61%
2016-12-31$6.44M-17.66%
2016-09-30$7.82M-88.15%
2016-06-30$66.01M810.19%
2016-03-31$7.25M-66.66%
2015-12-31$21.75M521.01%
2015-09-30$3.50M245.46%
2015-06-30$1.01M-31.99%
2015-03-31$1.49M-73.68%
2014-12-31$5.66M567.92%
2014-09-30$848.00K2.91%
2014-06-30$824.00K-62.27%
2014-03-31$2.18M25.23%
2013-12-31$1.74M-44.85%
2013-09-30$3.16M-19.36%
2013-06-30$3.92M191.52%
2013-03-31$1.34M-44.54%
2012-12-31$2.42M53.87%
2012-09-30$1.58M-

Xencor generated $16.96M in revenue during Q2 2024, up 32.45% compared to the previous quarter, and up 89.44% compared to the same period a year ago.

Xencor Revenue Breakdown

Xencor Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
License--$50.20M$112.20M-
Royalty$49.50M$152.10M$17.80M$5.00M-
Research collaboration$30.30M$7.00M$93.00M--
Milestone$88.50M$5.50M$21.00M$50.20M$23.20M
Royalties--$80.30M--
Licensing--$80.80M--
Collaboration---$4.50M$16.30M

Xencor's latest annual revenue breakdown by segment (product or service), as of Dec 23: Milestone (52.58%), Royalty (29.41%), and Research collaboration (18.00%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Non-cash Royalty$10.70M$12.30M------------------
Royalty--$7.90M$14.50M$13.30M$13.80M$16.20M$13.40M$7.30M$6.70M$6.10M$4.50M$3.80M$3.30M$2.50M$1.40M----
Milestone-$500.00K$27.50M$46.00M$10.00M$5.00M$500.00K--$5.00M$7.00M-$1.50M$12.50M$12.40M$25.00M$300.00K$12.50M$-100.00K$19.30M
Research collaboration--$9.20M$-1.30M$22.20M$200.00K$4.90M$100.00K$200.00K$1.80M$13.30M$6.30M--------
Royalties-------$27.20M$30.00M$78.70M$52.90M---------
Collaboration------------$58.60M$14.80M$1.30M$900.00K$1.50M$1.00M$1.10M$600.00K
License--------------$22.10M$5.00M$7.50M$15.60M-$500.00K

Xencor's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Non-cash Royalty (100.00%).

Xencor Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 20Dec 19Dec 18
Non United States$58.60M$14.00M-
U$64.10M$142.70M$40.60M

Xencor's latest annual revenue breakdown by geography, as of Dec 20: U (52.24%), and Non United States (47.76%).

Xencor Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
XNCRXencor$168.34M$16.96M
STROSutro Biopharma$153.73M$25.71M
ACLXArcellx$110.32M$26.03M
PTGXProtagonist Therapeutics$60.00M$4.67M
MRUSMerus$43.95M$11.77M
IDYAIDEAYA Biosciences$23.39M-
ANABAnaptysBio$17.16M$30.02M
MGTXMeiraGTx$14.02M$10.91M
VRDNViridian Therapeutics$314.00K$86.00K
KROSKeros Therapeutics$151.00K$37.00K
PCVXVaxcyte--
NUVLNuvalent--
REPLReplimune Group--
KURAKura Oncology--
ERASErasca--
SNDXSyndax Pharmaceuticals-$12.50M
MLYSMineralys Therapeutics--
LRMRLarimar Therapeutics--
GLUEMonte Rosa Therapeutics-$4.70M
EWTXEdgewise Therapeutics--

XNCR Revenue FAQ

What is Xencor’s yearly revenue?

Xencor's yearly revenue for 2023 was $168.34M, representing an increase of 2.28% compared to 2022. The company's yearly revenue for 2022 was $164.58M, representing a decrease of -40.18% compared to 2021. XNCR's yearly revenue for 2021 was $275.11M, representing an increase of 124.23% compared to 2020.

What is Xencor’s quarterly revenue?

Xencor's quarterly revenue for Q2 2024 was $16.96M, a 32.45% increase from the previous quarter (Q1 2024), and a -62.74% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $12.8M, a -71.35% decrease from the previous quarter (Q4 2023), and a -32.47% decrease year-over-year (Q1 2023). XNCR's quarterly revenue for Q4 2023 was $44.69M, a -24.47% decrease from the previous quarter (Q3 2023), and a 106.80% increase year-over-year (Q4 2022).

What is Xencor’s revenue growth rate?

Xencor's revenue growth rate for the last 3 years (2021-2023) was -38.81%, and for the last 5 years (2019-2023) was 7.43%.

What are Xencor’s revenue streams?

Xencor's revenue streams in c 23 are Royalty, Research collaboration, and Milestone. Royalty generated $49.5M in revenue, accounting 29.41% of the company's total revenue, down -67.46% year-over-year. Research collaboration generated $30.3M in revenue, accounting 18.00% of the company's total revenue, up 332.86% year-over-year. Milestone generated $88.5M in revenue, accounting 52.58% of the company's total revenue, up 1509.09% year-over-year.

What is Xencor’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Xencor was Milestone. This segment made a revenue of $88.5M, representing 52.58% of the company's total revenue.